Iron Chelation Therapy for Neurodegeneration

Overview

Executive Summary

Target: Brain iron accumulation in neurodegenerative diseases Approach: Use iron chelators (deferiprone, deferasirox, deferoxamine) to reduce brain iron levels and prevent iron-mediated oxidative damage Therapeutic Area: Alzheimer's Disease, Parkinson's Disease, Progressive Supranuclear Palsy, Corticobasal Syndrome Score: 74/100

Mechanism of Action

Iron Accumulation in Neurodegeneration

Overview

Executive Summary

Target: Brain iron accumulation in neurodegenerative diseases Approach: Use iron chelators (deferiprone, deferasirox, deferoxamine) to reduce brain iron levels and prevent iron-mediated oxidative damage Therapeutic Area: Alzheimer's Disease, Parkinson's Disease, Progressive Supranuclear Palsy, Corticobasal Syndrome Score: 74/100

Mechanism of Action

Iron Accumulation in Neurodegeneration

Brain iron accumulation is a characteristic finding in multiple neurodegenerative disorders. The basal ganglia, substantia nigra, and cortical regions show elevated iron levels in affected patients, with iron deposition increasing with disease progression[@martin2020]. Iron promotes oxidative stress through Fenton chemistry, generating hydroxyl radicals that damage lipids, proteins, and DNA[@halliwell1992].

Key mechanisms include:

• Oxidative stress: Iron catalyzes the formation of [reactive oxygen species](/entities/reactive-oxygen-species) (ROS), leading to lipid peroxidation and mitochondrial dysfunction[@jomova2010]
• Protein aggregation: Iron promotes the aggregation of [amyloid-beta](/proteins/amyloid-beta) (Aβ) in AD and [alpha-synuclein](/proteins/alpha-synuclein) in PD[@bansal2019]
• Neuroinflammation: Iron-activated microglia release pro-inflammatory cytokines, exacerbating neuronal death[@zhang2022]
• [Ferroptosis](/entities/ferroptosis): Iron-dependent programmed cell death has been implicated in neurodegeneration[@stockwell2017]

The FAIR-PARK Hypothesis

The FAIR-PARK hypothesis proposes that iron accumulation triggers parkinsonism through oxidative stress-induced neurodegeneration in the substantia nigra pars reticulata[@dexter1991]. Clinical evidence from MRI studies shows elevated iron in the substantia nigra of PD patients, correlating with disease severity[@wang2021].

Chelating Agents

Deferiprone

• Mechanism: Bidentate oral chelator that passes [BBB](/entities/blood-brain-barrier) and can mobilize brain iron
• Clinical evidence: FAIRPARK study showed reduced iron in substantia nigra and slower disease progression in PSP and PD[@devos2018]
• Dosing: 20-40 mg/kg/day oral, divided twice daily
• Monitoring: Weekly neutrophil count due to agranulocytosis risk

Deferasirox

• Mechanism: Tridentate oral chelator with better BBB penetration than deferoxamine[@guldberg2013]
• Clinical trials: Phase II trials in PD and PSP (FAIRPARK-II)
• Dosing: 20-40 mg/kg/day oral

Deferoxamine

• Mechanism: Hexadentate chelator that binds Fe³⁺ with high affinity
• Administration: Subcutaneous or intravenous infusion
• Challenges: Poor BBB penetration, rapid metabolism

Scoring (10-Dimension Rubric)

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 6 | Iron chelation is established in other contexts; repurposing for neurodegeneration |
| Mechanistic Rationale | 9 | Strong evidence for iron's role in oxidative stress and protein aggregation |
| Root-Cause Coverage | 8 | Addresses iron accumulation, a upstream pathological driver |
| Delivery Feasibility | 6 | Some agents cross BBB; deferiprone best brain penetration |
| Safety Plausibility | 6 | Known safety profile but agranulocytosis risk (deferiprone) |
| Combinability | 8 | Works with antioxidants, CoQ10, neuroprotective agents |
| Biomarker Availability | 9 | MRI iron quantification (R2*, SWI), oxidative stress biomarkers |
| De-risking Path | 8 | FAIRPARK trials provide proof-of-concept; existing approved agents |
| Multi-disease Potential | 9 | AD, PD, PSP, CBS, ALS - broad applicability |
| Patient Impact | 7 | Addresses fundamental aging-related pathology |

Total: 74/100

Clinical Evidence

Parkinson's Disease

• FAIRPARK trial: Demonstrated reduced iron in substantia nigra and slower disease progression with deferiprone[@devos2022]
• Combination therapy: Iron chelation combined with dopaminergic medications shows synergistic effects[@weinreb2013]

Progressive Supranuclear Palsy

• FAIR-PARK-II trial: Reduced brain iron levels on MRI with slower decline on PSP Rating Scale[@moreau2022]

Alzheimer's Disease

• Deferoxamine trial (1988): Crapper McLachlan et al. showed reduced rate of cognitive decline[@crapper1988]
• Deferasirox trials: Phase II studies showed reduced CSF biomarkers of oxidative stress

Combination Therapy Opportunities

Synergistic Targets

Preclinical Combination Data

• Deferiprone + CoQ10: Synergistic neuroprotection in PD models
• Deferasirox + N-acetylcysteine: Enhanced antioxidant effects

Development Pathway

Phase 1: Patient Selection

• Identify patients with elevated brain iron on MRI (R2*, SWI)
• Stratify by disease stage - early intervention most effective
• Select iron-accumulating disease subtypes (PD, PSP, CBS)

Phase 2: Combination Optimization

• Test deferiprone + CoQ10 in prodromal PD
• Evaluate deferasirox + vitamin D combination
• Optimize dosing to minimize agranulocytosis risk

Phase 3: Biomarker Validation

• Validate MRI iron quantification as prognostic biomarker
• Establish CSF ferritin as treatment response marker
• Develop point-of-care iron monitoring

Risks and Mitigations

| Risk | Mitigation |
|------|------------|
| Agranulocytosis (deferiprone) | Weekly CBC monitoring; dose titration |
| Iron deficiency | Monitor serum ferritin; maintain adequate levels |
| BBB penetration variability | Use brain-penetrant agents; optimize delivery |
| Limited efficacy in advanced disease | Early intervention; patient selection |

Competitive Landscape

Iron chelation for neurodegeneration is being pursued by:

• FAIRPARK consortium: Deferiprone in PD/PSP (Phase II)
• Neuroderm: Novel brain-penetrant iron chelators (preclinical)
• Various academic groups: Repurposing existing chelators

Cross-Links

Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Ferroptosis](/mechanisms/ferroptosis)

Mechanisms

• [Iron Metabolism](/mechanisms/iron-metabolism)
• [Oxidative Stress](/mechanisms/oxidative-stress)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Ferroptosis](/mechanisms/ferroptosis)

Proteins & Genes

• [Ferritin](/proteins/ferritin)
• [Transferrin](/proteins/transferrin)
• [DMT1](/genes/dmt1)
• [FPN](/genes/slc40a1)

Cell Types

• [Neurons](/cell-types/neurons)
• [Microglia](/cell-types/microglia-neuroinflammation)
• [Astrocytes](/cell-types/astrocytes)

Treatments

• [Iron Chelation Therapy](/therapeutics/iron-chelation-therapy)
• [Neuroprotective Agents](/therapeutics/neuroprotective-agents)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Actionable Next Steps

Implementation Roadmap

Phase 1: Discovery & Validation (Year 1)

| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Target validation | Months 1-3 | MRI iron quantification protocol standardization, patient stratification biomarkers | Research team |
| Lead compound selection | Months 4-6 | Compare deferiprone, deferasirox, novel chelators for brain penetration | Medicinal chemistry |
| In vitro proof-of-concept | Months 6-12 | iPSC neuron testing, dose-response, iron mobilization assays | Preclinical team |

Budget: $2-5M

Phase 2: Preclinical Development (Year 2)

| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Animal efficacy | Months 13-18 | MPTP/6-OHDA PD models, APP/PS1 AD models | In vivo pharmacology |
| GLP toxicology | Months 15-21 | 28-day, 90-day studies with focus on hematological safety | Toxicology |
| Formulation development | Months 18-24 | Brain-penetrant chelator optimization, combination formulation | Pharmaceutical development |

Budget: $8-15M

Phase 3: Clinical Development (Years 3-5)

| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Phase 1 | Months 24-30 | First-in-human safety, PK in neurodegeneration patients | Clinical operations |
| Phase 2a | Months 30-42 | Dose-finding, MRI iron reduction endpoints | Clinical development |
| Phase 2b | Months 42-60 | Registrational study in PSP/PD | Clinical development |

Budget: $30-50M (phased)

Key Academic Centers

• University of Lille, France (FAIRPARK consortium)
• Parkinson's UK Cambridge Brain Bank
• Mayo Clinic Rochester
• Columbia University Movement Disorders

Potential Partners

• Novartis (deferasirox franchise)
• Chiesi (rare disease pipeline)
• Takeda (neurology division)
• GTx (novel iron chelators)
• Biohaven (neuroprotection platform)

References